NCT07278089 (SAFE-ECHO) is a NA clinical trial of study arm in Atrial Fibrillation (AF), sponsored by Tze-Fan Chao.

Who is sponsoring NCT07278089?

NCT07278089 is sponsored by Tze-Fan Chao.

What drugs are being tested in NCT07278089?

Interventions in NCT07278089: study arm.

What condition does NCT07278089 study?

NCT07278089 studies Atrial Fibrillation (AF).

Is NCT07278089 still recruiting?

NCT07278089 is currently recruiting now. Last updated 11 December 2025.

Last reviewed 2025-12-11 · How we verify

NCT07278089: SAFE-ECHO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AF Screening in Patients With Abnormal Echocardiographic Parameters

Recruiting now NA Last updated 11 December 2025

What this trial tests

NA trial testing study arm in Atrial Fibrillation (AF) in 3,000 participants. Currently enrolling.

Timeline

17 March 2025

Primary endpoint
31 December 2031

31 December 2032

Quick facts

Lead sponsor	Tze-Fan Chao
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	3,000
Start date	17 March 2025
Primary completion	31 December 2031
Estimated completion	31 December 2032
Sites	1 location across Taiwan

Drugs / interventions tested

study arm

Conditions studied

Atrial Fibrillation (AF) — all drugs for Atrial Fibrillation (AF) →

Sponsor

Tze-Fan Chao

Who can join

20 and older, any sex, with Atrial Fibrillation (AF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the feasibility of specific echocardiographic parameters as criteria for AF screening and to determine the AF detection yield of scheduled extended ECG monitoring compared to contemporary care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Screening of Atrial Fibrillation/Arrhythmia Events in Patients With Abnormal ECHOcardiographic Parameters: The Randomized, Prospective SAFE-ECHO Study Design and Rationale.
Liao JN, Kuo L, Liu CM, Tsai CT, et al · · 2026 · PMID 41999845 · DOI 10.1016/j.amjcard.2026.03.074

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation (AF)

Currently open trials in the same condition.

NCT07298473 — Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sp · NA · recruiting
NCT07442175 — Blood Pressure Monitor (TH-75) Atrial Fibrillation Detection Function Clinical Trial · recruiting
NCT07389434 — Feasibility, Safety, Cost-effectiveness, and Environmental Impact of Reprocessed Ablation Catheters in PVI · NA · recruiting
NCT07250529 — Left Bundle Branch Pacing vs Right Ventricular Pacing on AHRE Burden in Patients With Preserved LVEF · NA · recruiting
NCT07358611 — Non-invasive Mapping-Guided Atrial Fibrillation Ablation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07278089 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tze-Fan Chao
Last refreshed: 11 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07278089.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing